Catalyst Pharma Unveils New Equity Incentive Plan
Ticker: CPRX · Form: 8-K · Filed: May 21, 2024 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-incentive, compensation, stock-plan
Related Tickers: CPRX
TL;DR
Catalyst Pharma just dropped a new stock incentive plan, reserving 3.5M shares for employees and execs.
AI Summary
Catalyst Pharmaceuticals, Inc. announced on May 21, 2024, that its Board of Directors has approved a new equity incentive plan, the 2024 Equity Incentive Plan. This plan allows for the granting of stock options, restricted stock units, and other equity-based awards to employees, directors, and consultants. The company has reserved 3,500,000 shares of common stock for issuance under this new plan.
Why It Matters
The new equity plan signals management's intent to retain and incentivize key personnel by offering stock-based compensation, which can align employee interests with shareholder value.
Risk Assessment
Risk Level: low — The filing is a routine announcement of an equity incentive plan, which is common practice for public companies and does not inherently introduce new business risks.
Key Numbers
- 3,500,000 — Shares Reserved (Under the new 2024 Equity Incentive Plan for employees, directors, and consultants.)
Key Players & Entities
- Catalyst Pharmaceuticals, Inc. (company) — Registrant
- 2024 Equity Incentive Plan (plan) — New equity incentive plan approved by the Board of Directors
- 3,500,000 (dollar_amount) — Number of common stock shares reserved for issuance under the new plan
FAQ
What is the primary purpose of the 2024 Equity Incentive Plan?
The plan is designed to provide incentives to employees, directors, and consultants of Catalyst Pharmaceuticals, Inc. through the granting of stock options, restricted stock units, and other equity-based awards.
How many shares of common stock are reserved for issuance under the new plan?
A total of 3,500,000 shares of common stock are reserved for issuance under the 2024 Equity Incentive Plan.
Who is eligible to receive awards under the new equity plan?
Employees, directors, and consultants of Catalyst Pharmaceuticals, Inc. are eligible to receive awards under the plan.
When was the 2024 Equity Incentive Plan approved?
The 2024 Equity Incentive Plan was approved by the Board of Directors on May 21, 2024.
What types of equity awards can be granted under the plan?
The plan allows for the granting of stock options, restricted stock units, and other equity-based awards.
Filing Stats: 611 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-21 17:28:36
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d786039d8k.htm (8-K) — 38KB
- 0001193125-24-144049.txt ( ) — 158KB
- cprx-20240521.xsd (EX-101.SCH) — 3KB
- cprx-20240521_lab.xml (EX-101.LAB) — 18KB
- cprx-20240521_pre.xml (EX-101.PRE) — 11KB
- d786039d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael Kalb Michael Kalb Executive Vice President and CFO Dated: May 21, 2024 4